|
1
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mamelak AN and Jacoby DB: Targeted
delivery of antitumoral therapy to glioma and other malignancies
with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv.
4:175–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Macartney G, Harrison MB, VanDenKerkhof E,
Stacey D and McCarthy P: Quality of life and symptoms in pediatric
brain tumor survivors: A systematic review. J Pediatr Oncol Nurs.
31:65–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rice T, Lachance DH, Molinaro AM,
Eckel-Passow JE, Walsh KM, Barnholtz-Sloan J, Ostrom QT, Francis
SS, Wiemels J, Jenkins RB, et al: Understanding inherited genetic
risk of adult glioma-a review. Neurooncol Pract. 3:10–16.
2016.PubMed/NCBI
|
|
5
|
Radner H, el-Shabrawi Y, Eibl RH, Brüstle
O, Kenner L, Kleihues P and Wiestler OD: Tumor induction by ras and
myc oncogenes in fetal and neonatal brain: Modulating effects of
developmental stage and retroviral dose. Acta Neuropathol.
86:456–465. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sah NK, Khan Z, Khan GJ and Bisen PS:
Structural, functional and therapeutic biology of survivin. Cancer
Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jaiswal PK, Goel A and Mittal RD:
Survivin: A molecular biomarker in cancer. Indian J Med Res.
141:389–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and tumorigenesis: Molecular mechanisms and therapeutic
strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garg H, Suri P, Gupta JC, Talwar GP and
Dubey S: Survivin: A unique target for tumor therapy. Cancer Cell
Int. 16:492016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen H, Yang F, Li X, Gong ZJ and Wang LW:
Long noncoding RNA LNC473 inhibits the ubiquitination of survivin
via association with USP9X and enhances cell proliferation and
invasion in hepatocellular carcinoma cells. Biochem Biophys Res
Commun. 499:702–710. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang R, Qu S, Liang H, Chen X, Zhang C and
Guo H: Long noncoding RNA H19 regulates survivin expression in
bladder cancer as sponge of miR-138-5p. Eur Urol Suppl.
16:e1464–e1465. 2017. View Article : Google Scholar
|
|
13
|
Lin A, Li C, Xing Z, Hu Q, Liang K, Han L,
Wang C, Hawke DH, Wang S, Zhang Y, et al: The LINK-A lncRNA
activates normoxic HIF1α signalling in triple-negative breast
cancer. Nat Cell Biol. 18:213–224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang F, Chu J and Wang F: Expression and
clinical significance of cyclooxygenase 2 and survivin in human
gliomas. Oncol Lett. 14:1303–1308. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lv S, Dai C, Liu Y, Shi R, Tang Z, Han M,
Bian R, Sun B and Wang R: Retraction note to: The impact of
survivin on prognosis and clinicopathology of glioma patients: A
systematic meta-analysis. Mol Neurobiol. 54:23762017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jane EP, Premkumar DR, Sutera PA, Cavaleri
JM and Pollack IF: Survivin inhibitor YM155 induces mitochondrial
dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced
glioma cell lines. Mol Carcinog. 56:1251–1265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Sun S, Pu JK, Tsang AC, Lee D,
Man VO, Lui WM, Wong ST and Leung GK: Long non-coding RNA
expression profiles predict clinical phenotypes in glioma.
Neurobiol Dis. 48:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang P, Ren Z and Sun P: Overexpression of
the long non-coding RNA MEG3 impairs in vitro glioma cell
proliferation. J Cell Biochem. 113:1868–1874. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Wei DL, Wan L, Yan SF and Sun YH:
Highly expressed lncRNA CCND2-AS1 promotes glioma cell
proliferation through Wnt/β-catenin signaling. Biochem Biophys Res
Commun. 482:1219–1225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo
Y, Peng R and Cheng L: LncRNA CASC2 interacts with miR-181a to
modulate glioma growth and resistance to TMZ through PTEN pathway.
J Cell Biochem. 118:1889–1899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin A, Hu Q, Li C, Xing Z, Ma G, Wang C,
Li J, Ye Y, Yao J, Liang K, et al: The LINK-A lncRNA interacts with
PtdIns(3,4,5)P3 to hyperactivate AKT and confer
resistance to AKT inhibitors. Nat Cell Biol. 19:238–251. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kopreski MS, Benko FA, Kwak LW and Gocke
CD: Detection of tumor messenger RNA in the serum of patients with
malignant melanoma. Clin Cancer Res. 5:1961–1965. 1999.PubMed/NCBI
|
